Biomarker Discovery Grant Deadline Extended
RayBiotech, Inc., today announced that they are extending the deadline for submitting applications for its Biomarker Discovery Pilot Grant program. RayBiotech will now accept applications for the pilot grants through February 22nd, 2010. “The last-minute surge in interest in the grant program has been overwhelming,” said Brett Burkholder, Director of Marketing & Business Development for RayBiotech, Inc.
Norcross, GA, February 02, 2010 --(PR.com)-- RayBiotech, Inc., today announced that they are extending the deadline for submitting applications for its Biomarker Discovery Pilot Grant program. RayBiotech will now accept applications for the pilot grants through February 22nd, 2010. Grant recipients will receive restricted grants of $10,000 to $20,000 worth of RayBiotech products and/or services for conducting biomarker research.
“The last-minute surge in interest in the grant program has been overwhelming,” said Brett Burkholder, Director of Marketing & Business Development for RayBiotech, Inc. “Investigators are excited about the prospect of accelerating their biomarker research using our antibody-based screening technologies.”
The application of antibody arrays to biomarker discovery was well-illustrated in the November 2007 edition of the peer-reviewed scientific journal, Nature Medicine (Ray, et al.). Using a technique known as signal profiling that was enabled by RayBiotech Cytokine Antibody Arrays, they were able to simultaneously measure the relative abundance of 120 plasma markers measured in the Nature Medicine study. Using this method, the group identified a panel of 18 biomarkers that predicted the presence of the disease in a test sample set with nearly 90 percent accuracy.
Details of RayBiotech’s Biomarker Discovery Pilot Grant Program, including terms and conditions of the grant program and application forms, please visit their Website at http://www.RayBiotech.com/Grant.
About RayBiotech
RayBiotech, Inc., introduced the first commercially available cytokine antibody array in 2001. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA) and many others. Offering more antibody array choices than any of its competitors, RayBiotech continues to lead in the development of protein array technologies. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
Contact:
Brett Burkholder, Dir. Marketing & Business Development
RayBiotech, Inc.
Email: grant@raybiotech.com
Web: http://www.RayBiotech.com/Grant
###
“The last-minute surge in interest in the grant program has been overwhelming,” said Brett Burkholder, Director of Marketing & Business Development for RayBiotech, Inc. “Investigators are excited about the prospect of accelerating their biomarker research using our antibody-based screening technologies.”
The application of antibody arrays to biomarker discovery was well-illustrated in the November 2007 edition of the peer-reviewed scientific journal, Nature Medicine (Ray, et al.). Using a technique known as signal profiling that was enabled by RayBiotech Cytokine Antibody Arrays, they were able to simultaneously measure the relative abundance of 120 plasma markers measured in the Nature Medicine study. Using this method, the group identified a panel of 18 biomarkers that predicted the presence of the disease in a test sample set with nearly 90 percent accuracy.
Details of RayBiotech’s Biomarker Discovery Pilot Grant Program, including terms and conditions of the grant program and application forms, please visit their Website at http://www.RayBiotech.com/Grant.
About RayBiotech
RayBiotech, Inc., introduced the first commercially available cytokine antibody array in 2001. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA) and many others. Offering more antibody array choices than any of its competitors, RayBiotech continues to lead in the development of protein array technologies. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
Contact:
Brett Burkholder, Dir. Marketing & Business Development
RayBiotech, Inc.
Email: grant@raybiotech.com
Web: http://www.RayBiotech.com/Grant
###
Contact
RayBiotech
Brett Burkholder
770-729-2992
http://www.raybiotech.com
Brett Burkholder
770-729-2992
http://www.raybiotech.com
Contact
Categories